Trial Profile
A Double Blind (3rd Party Open) Randomized, Placebo Controlled, Crossover Dose Escalation Study To Investigate The Safety, Toleration, Pharmacokinetics And Exploratory Pharmacodynamics Of PF-05089771 In Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2022
Price :
$35
*
At a glance
- Drugs PF 5089771 (Primary)
- Indications Pain
- Focus Adverse reactions; Biomarker; First in man; Pharmacodynamics; Pharmacokinetics
- Acronyms FIH SAD study
- Sponsors Pfizer
- 18 Sep 2022 Results presented at the 26th International Congress of Parkinson's Disease and Movement Disorders
- 19 Feb 2016 Results of two phase I studies published in the Clinical Pharmacokinetics
- 30 Jan 2012 Actual patient number is 61 according to ClinicalTrials.gov.